US6228871B1
(en)
|
1995-07-10 |
2001-05-08 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
DK0880508T3
(da)
|
1996-02-13 |
2003-06-30 |
Astrazeneca Ab |
Quinazolinderivater som VEGF-inhibitorer
|
ATE211134T1
(de)
|
1996-03-05 |
2002-01-15 |
|
4-anilinochinazolin derivate
|
CZ295468B6
(cs)
|
1996-04-12 |
2005-08-17 |
Warner-Lambert Company |
Polycyklické sloučeniny
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
ATE229019T1
(de)
|
1996-06-27 |
2002-12-15 |
Janssen Pharmaceutica Nv |
N-4-(heteroarylmethyl)phenyl- heteroarylaminderivate
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
KR100567649B1
(ko)
|
1996-09-25 |
2006-04-05 |
아스트라제네카 유케이 리미티드 |
혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
|
JP2009007364A
(ja)
*
|
1996-10-15 |
2009-01-15 |
Astrazeneca Uk Ltd |
キナゾリン誘導体
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
ZA986729B
(en)
*
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
US6465484B1
(en)
|
1997-09-26 |
2002-10-15 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
US6162804A
(en)
*
|
1997-09-26 |
2000-12-19 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
FR2772763B1
(fr)
*
|
1997-12-24 |
2004-01-23 |
Sod Conseils Rech Applic |
Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
KR100722194B1
(ko)
|
1998-06-02 |
2007-05-29 |
오에스아이 파마슈티컬스, 인코포레이티드 |
피롤로[2,3디]피리미딘 조성물 및 이의 용도
|
US20040067227A1
(en)
*
|
2001-11-02 |
2004-04-08 |
Goldstein Allan L. |
Inhibition or reversal of skin aging by actin-sequestering peptides
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
HU228964B1
(en)
|
1999-02-10 |
2013-07-29 |
Astrazeneca Ab |
Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing them
|
US7049410B2
(en)
*
|
1999-05-14 |
2006-05-23 |
Majumdar Adhip P N |
Antibodies to a novel EGF-receptor related protein (ERRP)
|
AU5003200A
(en)
|
1999-05-14 |
2000-12-05 |
United States Of America As Represented By The Department Of Veterans Affairs, The |
Isolation and characterization of epidermal growth factor related protein
|
NZ516633A
(en)
|
1999-06-21 |
2004-09-24 |
Boehringer Ingelheim Pharma |
Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
CA2384291A1
(fr)
*
|
1999-09-21 |
2001-03-29 |
Astrazeneca Ab |
Derives de quinazoline et leur utilisation comme produits pharmaceutiques
|
WO2001021594A1
(fr)
|
1999-09-21 |
2001-03-29 |
Astrazeneca Ab |
Composes de quinazoline et compositions pharmaceutiques comprenant lesdits composes
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
ES2265998T3
(es)
|
1999-11-05 |
2007-03-01 |
Astrazeneca Ab |
Derivados de quizazolina como inhibidores de vegf.
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
JP2003518023A
(ja)
*
|
1999-11-30 |
2003-06-03 |
パーカー ヒューズ インスティテュート |
トロンビン誘導血小板凝集の阻害剤
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US7160890B2
(en)
*
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
MXPA02007632A
(es)
|
2000-02-07 |
2004-08-23 |
Abbott Gmbh & Co Kg |
Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
AUPQ592100A0
(en)
*
|
2000-02-29 |
2000-03-23 |
Council Of The Queensland Institute Of Medical Research, The |
A method of treatment and prophylaxis
|
AU2001235804A1
(en)
*
|
2000-03-06 |
2001-09-17 |
Astrazeneca Ab |
Therapy
|
US20070021392A1
(en)
*
|
2000-03-31 |
2007-01-25 |
Davis Peter D |
Divided dose therapies with vascular damaging activity
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
WO2001077085A1
(fr)
*
|
2000-04-07 |
2001-10-18 |
Astrazeneca Ab |
Composes a base de quinazoline
|
UA73993C2
(uk)
*
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
PL202812B1
(pl)
|
2000-08-21 |
2009-07-31 |
Astrazeneca Ab |
Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
AU2001293233A1
(en)
|
2000-09-01 |
2002-03-13 |
Chiron Corporation |
Aza heterocyclic derivatives and their therapeutic use
|
US20030028018A1
(en)
*
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
SG129306A1
(en)
*
|
2000-09-11 |
2007-02-26 |
Chiron Corp |
Quinolinone derivatives as tyrosine kinase inhibitors
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
EP1330444B1
(fr)
|
2000-11-01 |
2011-03-23 |
Millennium Pharmaceuticals, Inc. |
Composes heterocycliques azotes et leur procede de fabrication
|
AU2001229722A1
(en)
*
|
2000-11-29 |
2002-06-11 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6680324B2
(en)
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US7019012B2
(en)
*
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
ATE430742T1
(de)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
EP1399483B1
(fr)
|
2001-01-05 |
2010-04-14 |
Pfizer Inc. |
Anticorps anti-recepteur du facteur de croissance insulinoide i
|
US20070050857A1
(en)
*
|
2001-02-28 |
2007-03-01 |
Hayward Nick K |
Method of treatment and prophylaxis
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
WO2002092578A1
(fr)
*
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Derives de quinazoline
|
EP1408980A4
(fr)
|
2001-06-21 |
2004-10-20 |
Ariad Pharma Inc |
Nouvelles quinazolines et leur utilisation
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
JP4836368B2
(ja)
*
|
2001-08-30 |
2011-12-14 |
広栄化学工業株式会社 |
メチルヒドロキシアルキルピリジン類の製造方法
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
WO2003040108A1
(fr)
*
|
2001-11-03 |
2003-05-15 |
Astrazeneca Ab |
Derives quinazoline utilises en tant qu'agents antitumoraux
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
AU2002360436A1
(en)
*
|
2001-11-30 |
2003-06-17 |
Osi Pharmaceuticals, Inc. |
2-aryl pyrrologpyrimidines for a1 and a3 receptors
|
WO2003051849A1
(fr)
*
|
2001-12-19 |
2003-06-26 |
Ube Industries, Ltd. |
Procede de production de quinazoline-4-one et derive de celle-ci
|
DE60236458D1
(de)
*
|
2001-12-20 |
2010-07-01 |
Osi Pharm Inc |
Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
|
CA2471059C
(fr)
|
2001-12-20 |
2011-04-26 |
Osi Pharmaceuticals, Inc. |
Composes pyrimidine antagonistes selectifs des recepteurs a<sb>2b</sb>, leur synthese et leur utilisation
|
EP1477481B1
(fr)
*
|
2002-01-28 |
2009-07-22 |
Ube Industries, Ltd. |
Procede de production de derive de quinazolin-4-one
|
ATE549329T1
(de)
*
|
2002-02-01 |
2012-03-15 |
Astrazeneca Ab |
Chinazoline verbindungen
|
CA2478050A1
(fr)
|
2002-03-01 |
2003-09-12 |
Pfizer Inc. |
Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
|
TW200813014A
(en)
*
|
2002-03-28 |
2008-03-16 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
US6936641B2
(en)
*
|
2002-06-25 |
2005-08-30 |
Johnson & Johnson Vision Care, Inc. |
Macromer forming catalysts
|
CA2491191C
(fr)
*
|
2002-07-15 |
2014-02-04 |
Exelixis, Inc. |
Modulateurs de kinase de type recepteur et procedes d'utilisation
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
JPWO2004018430A1
(ja)
*
|
2002-08-23 |
2005-12-08 |
麒麟麦酒株式会社 |
TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
|
BR0313743A
(pt)
*
|
2002-08-23 |
2005-07-05 |
Chiron Corp |
Benzimidazol quinolinonas e usos destas
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
US20050256157A1
(en)
*
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
DE60318219T2
(de)
|
2002-08-24 |
2009-01-15 |
Astrazeneca Ab |
PYRIMIDINDERIVATE ALS MODULATOREN DER AKTIVITuT VON CHEMOKINREZEPTOREN
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
PT1562955E
(pt)
*
|
2002-11-04 |
2008-05-05 |
Astrazeneca Ab |
Derivados de quinazolina como inibidores da scr tirosina-cinase
|
NZ539425A
(en)
*
|
2002-11-13 |
2007-11-30 |
Chiron Corp |
Methods of treating cancer and related methods
|
PL377713A1
(pl)
|
2002-12-19 |
2006-02-06 |
Pfizer Inc. |
Związki 2-(1H-indazol-6-iloamino)benzamidowe jako inhibitory kinaz białkowych użyteczne w leczeniu chorób oczu
|
EP1578755B1
(fr)
|
2002-12-24 |
2007-08-22 |
AstraZeneca AB |
Derives de phosphonooxy quinazoline et leur utilisation pharmaceutique
|
US7223749B2
(en)
*
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
KR101106905B1
(ko)
|
2003-02-26 |
2012-01-25 |
수젠, 인크. |
단백질 키나아제 억제제로서의 아미노헤테로아릴 화합물
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
PL1660057T3
(pl)
|
2003-08-27 |
2012-10-31 |
Ophthotech Corp |
Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej
|
MXPA06002296A
(es)
|
2003-08-29 |
2006-05-22 |
Pfizer |
Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
CA2539022A1
(fr)
*
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Derives de quinozaline en tant qu'inhibiteurs de la tyrosine kinase
|
GB0321648D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Astrazeneca Ab |
Quinazoline derivatives
|
SI1667991T1
(sl)
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Kinazolinski derivati kot inhibitorji tirozin kinaze
|
DK1667992T3
(da)
*
|
2003-09-19 |
2007-04-30 |
Astrazeneca Ab |
Quinazolinderivater
|
US20070037837A1
(en)
*
|
2003-09-19 |
2007-02-15 |
Hennequin Laurent Francois A |
Quinazoline derivatives
|
KR20060100388A
(ko)
*
|
2003-09-25 |
2006-09-20 |
아스트라제네카 아베 |
퀴나졸린 유도체
|
ES2466818T3
(es)
*
|
2003-09-26 |
2014-06-11 |
Exelixis, Inc. |
Moduladores c-Met y métodos de uso
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
ES2372694T3
(es)
|
2003-10-15 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
|
AU2004288709B2
(en)
*
|
2003-11-07 |
2011-01-06 |
Novartis Vaccines And Diagnostics, Inc. |
Methods for synthesizing quinolinone compounds
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2004293017B2
(en)
|
2003-11-19 |
2010-08-19 |
Array Biopharma Inc. |
Bicyclic inhibitors of MEK and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
OA13349A
(en)
|
2003-12-23 |
2007-04-13 |
Pfizer |
Novel quinoline derivatives.
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP2305671A1
(fr)
|
2004-01-05 |
2011-04-06 |
AstraZeneca AB |
Dérivés de thiophène et thiazole comme inhibiteurs de CHK 1
|
EP1713484A2
(fr)
|
2004-01-23 |
2006-10-25 |
Amgen Inc. |
Composes et leurs procedes d'utilisation
|
EP1724268A4
(fr)
*
|
2004-02-20 |
2010-04-21 |
Kirin Pharma Kk |
Compose ayant une activite d'inhibition du tgf-beta et composition pharmaceutique contenant celui-ci
|
JP5019884B2
(ja)
*
|
2004-02-20 |
2012-09-05 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
炎症プロセスおよび転移プロセスの調節
|
UA89493C2
(uk)
|
2004-04-02 |
2010-02-10 |
Оси Фармасьютикалз, Инк. |
6,6-біциклічні кільцеві заміщені гетеробіциклічні інгібітори протеїнкіназ
|
AP2204A
(en)
|
2004-05-06 |
2011-02-07 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amides.
|
CN1993349A
(zh)
*
|
2004-06-04 |
2007-07-04 |
阿斯利康(瑞典)有限公司 |
作为erbb受体酪氨酸激酶的喹唑啉衍生物
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
KR20070036130A
(ko)
|
2004-07-16 |
2007-04-02 |
화이자 프로덕츠 인코포레이티드 |
항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
|
AR053090A1
(es)
|
2004-07-20 |
2007-04-25 |
Osi Pharm Inc |
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
|
EA013678B1
(ru)
|
2004-08-26 |
2010-06-30 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
|
BRPI0514735B8
(pt)
|
2004-08-28 |
2021-05-25 |
Astrazeneca Ab |
derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
|
AU2005312048B2
(en)
|
2004-11-30 |
2012-08-02 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
ES2371083T3
(es)
|
2004-12-21 |
2011-12-27 |
Medimmune Limited |
Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
|
GB0428526D0
(en)
|
2004-12-30 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
KR101387985B1
(ko)
*
|
2005-01-27 |
2014-04-25 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
전이 종양의 치료
|
ME02645B
(fr)
|
2005-02-04 |
2012-04-30 |
Astrazeneca Ab |
Dérivés de pyrazolylaminopyridine employés en tant qu'inhibiteurs de kinase
|
AU2006216266C1
(en)
*
|
2005-02-23 |
2010-08-26 |
Shionogi & Co., Ltd. |
Quinazoline derivative having tyrosine kinase inhibitory activity
|
KR20070107151A
(ko)
*
|
2005-02-26 |
2007-11-06 |
아스트라제네카 아베 |
티로신 키나제 억제제로서의 퀴나졸린 유도체
|
GB0504474D0
(en)
*
|
2005-03-04 |
2005-04-13 |
Astrazeneca Ab |
Chemical compounds
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
BRPI0608096A2
(pt)
|
2005-04-26 |
2009-11-10 |
Pfizer |
anticorpos p-caderina
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
GB0508717D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
CN1858040B
(zh)
*
|
2005-05-08 |
2011-04-06 |
中国科学院上海药物研究所 |
5,8-二取代喹唑啉及其制备方法和用途
|
AU2006247803B2
(en)
|
2005-05-13 |
2011-12-22 |
Novartis Ag |
Methods for treating drug resistant cancer
|
EP1888556B1
(fr)
|
2005-05-17 |
2011-10-26 |
Novartis AG |
Procede de synthese de composes heterocycliques
|
ES2378760T3
(es)
|
2005-05-18 |
2012-04-17 |
Array Biopharma, Inc. |
Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
|
CN102070614B
(zh)
|
2005-05-23 |
2014-01-15 |
诺华股份有限公司 |
4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
|
EP1912941B1
(fr)
|
2005-07-21 |
2012-11-14 |
AstraZeneca AB |
Derives de piperidine
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
US7566721B2
(en)
*
|
2005-08-08 |
2009-07-28 |
Osi Pharmaceuticals, Inc. |
Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
KR101390127B1
(ko)
|
2005-09-07 |
2014-05-13 |
암젠 프레몬트 인코포레이티드 |
액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
|
DK1926996T3
(da)
|
2005-09-20 |
2012-01-23 |
Osi Pharmaceuticals Llc |
Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
|
US20090239861A1
(en)
*
|
2005-09-20 |
2009-09-24 |
Robert Hugh Bradbury |
Quinazoline derivatives as anticancer agents
|
EP1928861B1
(fr)
|
2005-09-20 |
2010-11-17 |
AstraZeneca AB |
Composés de 4- (ih-indazol-5-yl-amino)-quinazoline utilisés comme inhibiteurs des recepteurs erbb des tyrosines kinases pour traiter le cancer
|
EP1939199A4
(fr)
|
2005-09-22 |
2010-10-20 |
Dainippon Sumitomo Pharma Co |
Nouveau compose d'adenine
|
EP1939201A4
(fr)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
Nouveau composé adénine
|
US20090192153A1
(en)
|
2005-09-22 |
2009-07-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
JPWO2007034916A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
GB0519879D0
(en)
|
2005-09-30 |
2005-11-09 |
Astrazeneca Ab |
Chemical process
|
WO2007039736A1
(fr)
|
2005-10-06 |
2007-04-12 |
Astrazeneca Ab |
Nouveaux composes
|
DK1945631T3
(da)
|
2005-10-28 |
2012-10-22 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
|
EP1948179A1
(fr)
|
2005-11-11 |
2008-07-30 |
Boehringer Ingelheim International GmbH |
Derives de quinazoline pour le traitement des affections cancereuses
|
ES2364901T3
(es)
|
2005-11-15 |
2011-09-16 |
Array Biopharma, Inc. |
Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
|
AU2006320591B2
(en)
|
2005-11-29 |
2010-06-03 |
Novartis Ag |
Formulations of quinolinones
|
EP1960371B1
(fr)
*
|
2005-12-02 |
2009-09-16 |
AstraZeneca AB |
Derives de quinazoline utilises en tant qu inhibiteurs des tyrosine kinases erbb associees au recepteur
|
EP1957499A1
(fr)
*
|
2005-12-02 |
2008-08-20 |
AstraZeneca AB |
Dérivés de la quinazoline à substitution 4-anilino comme inhibiteurs de la tyrosine kinase
|
AR057960A1
(es)
*
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
ES2385054T3
(es)
|
2005-12-13 |
2012-07-17 |
Medimmune Limited |
Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
|
JP2009519308A
(ja)
|
2005-12-15 |
2009-05-14 |
アストラゼネカ・アクチエボラーグ |
呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン
|
US8575164B2
(en)
*
|
2005-12-19 |
2013-11-05 |
OSI Pharmaceuticals, LLC |
Combination cancer therapy
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CA2651629A1
(fr)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Derives d'acide cycloalkylamine et compositions pharmaceutiques a base de ceux-ci
|
US7741360B2
(en)
|
2006-05-26 |
2010-06-22 |
Astrazeneca Ab |
Bi-aryl or aryl-heteroaryl substituted indoles
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
HUE033894T2
(en)
*
|
2006-08-23 |
2018-01-29 |
Kudos Pharm Ltd |
2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
|
PT2068880E
(pt)
*
|
2006-09-18 |
2012-07-12 |
Boehringer Ingelheim Int |
Método para tratamento do cancro apresentando mutações no egfr
|
US7851623B2
(en)
|
2006-11-02 |
2010-12-14 |
Astrazeneca Ab |
Chemical process
|
EP1921070A1
(fr)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
US7799954B2
(en)
|
2006-11-17 |
2010-09-21 |
Abraxis Bioscience, Llc |
Dicarbonyl derivatives and methods of use
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
KR20090094460A
(ko)
|
2006-12-19 |
2009-09-07 |
아스트라제네카 아베 |
무스카린 수용체 길항제로서 퀴누클리디놀 유도체
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
KR20090116782A
(ko)
|
2007-02-06 |
2009-11-11 |
베링거 인겔하임 인터내셔날 게엠베하 |
바이사이클릭 헤테로사이클, 당해 화합물을 함유하는 약물, 이의 용도 및 이의 제조방법
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
US8148532B2
(en)
|
2007-03-14 |
2012-04-03 |
Guoqing Paul Chen |
Spiro substituted compounds as angiogenesis inhibitors
|
TW200902018A
(en)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
JPWO2008114819A1
(ja)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
ES2424745T3
(es)
|
2007-09-07 |
2013-10-08 |
Agensys, Inc. |
Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12
|
EP2207788A1
(fr)
|
2007-10-04 |
2010-07-21 |
AstraZeneca AB |
Composés [3, 2-c]pyrazole stéroïdes à activité glucocorticoïde
|
CN101861321B
(zh)
|
2007-10-11 |
2013-02-06 |
阿斯利康(瑞典)有限公司 |
作为蛋白激酶b抑制剂的吡咯并[2,3-d]嘧啶衍生物
|
NZ586802A
(en)
|
2007-12-19 |
2012-03-30 |
Genentech Inc |
Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases
|
EP3211010A1
(fr)
|
2007-12-21 |
2017-08-30 |
Medimmune Limited |
Éléments de liaison pour le récepteur alpha interleukin-4 (il-4r) - 173
|
CA2708176A1
(fr)
|
2007-12-21 |
2009-07-02 |
Genentech, Inc. |
Azaindolizines et procedes d'utilisation
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2009091939A1
(fr)
*
|
2008-01-18 |
2009-07-23 |
Osi Pharmaceuticals, Inc. |
Dérivés d'imidazopyrazinol pour le traitement des cancers
|
WO2009094210A1
(fr)
*
|
2008-01-22 |
2009-07-30 |
Concert Pharmaceuticals Inc. |
Dérivés de vandetanib
|
JP2011510079A
(ja)
*
|
2008-01-22 |
2011-03-31 |
コンサート ファーマシューティカルズ インコーポレイテッド |
ゲフィチニブ誘導体
|
CA2711582A1
(fr)
|
2008-02-07 |
2009-08-13 |
Boehringer Ingelheim International Gmbh |
Heterocycles spirocycliques, formules comportant lesdits composes, leur utilisation et procedes de preparation associes
|
CN101952287B
(zh)
|
2008-02-28 |
2013-11-27 |
默克专利有限公司 |
蛋白激酶抑制剂及其应用
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
US8088782B2
(en)
|
2008-05-13 |
2012-01-03 |
Astrazeneca Ab |
Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
|
ES2396613T3
(es)
*
|
2008-05-19 |
2013-02-22 |
OSI Pharmaceuticals, LLC |
Imidazopirazinas e imidazotriazinas sustituidas
|
PL2297106T3
(pl)
|
2008-05-27 |
2015-01-30 |
Galderma Sa |
Pochodne fenoksypirydynyloamidu i ich zastosowania w leczeniu chorób, w których pośredniczy pde4
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
TWI461423B
(zh)
|
2008-07-02 |
2014-11-21 |
Astrazeneca Ab |
用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
|
CA2733153C
(fr)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Heterocycles a substitution cyclohexyloxy, medicaments contenant ces composes, leur utilisation et procedes pour les preparer
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
US8211911B2
(en)
|
2008-08-19 |
2012-07-03 |
Guoqing Paul Chen |
Compounds as kinase inhibitors
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
EP2334701A4
(fr)
|
2008-10-16 |
2014-01-08 |
Univ Pittsburgh |
Anticorps entièrement humains dirigés contre un antigène associé au mélanome de masse moléculaire élevée et leurs utilisations
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(fr)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Dérivés de diazaspiro[5.5]undécane et composés associés utilisés comme antagonistes des récepteurs muscariniques et agonistes des récepteurs bêta adrénergiques dans le traitement des affections pulmonaires
|
CN104860913B
(zh)
|
2008-12-11 |
2018-05-04 |
艾克赛特药品有限公司 |
染料木黄酮的晶型
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
WO2010077530A1
(fr)
|
2008-12-17 |
2010-07-08 |
Merck Patent Gmbh |
Inhibiteurs de protéines kinases de type benzonaphtyridinones tricycliques modifiées sur le noyau c et leur utilisation
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
JP2012512871A
(ja)
|
2008-12-18 |
2012-06-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
三環式アザインドール
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
AU2009331528A1
(en)
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
TWI447108B
(zh)
|
2009-01-16 |
2014-08-01 |
Exelixis Inc |
N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型
|
AU2010210646B2
(en)
|
2009-02-05 |
2015-10-29 |
Immunogen, Inc. |
Novel benzodiazepine derivatives
|
WO2010089580A1
(fr)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Utilisation d'un inhibiteur de mct1 de traitement du cancer exprimant mct1 sur mct4
|
CN102307875A
(zh)
|
2009-02-09 |
2012-01-04 |
苏伯俭股份有限公司 |
吡咯并嘧啶基axl激酶抑制剂
|
WO2010092371A1
(fr)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Dérivés de triazolo[4,3-b]pyridazine et leurs utilisations contre le cancer de la prostate
|
WO2010099139A2
(fr)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Thérapie anti-cancer combinée
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(fr)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
|
WO2010099138A2
(fr)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
|
TW201035088A
(en)
|
2009-02-27 |
2010-10-01 |
Supergen Inc |
Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
JP2012524119A
(ja)
|
2009-04-20 |
2012-10-11 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
C−ピラジン−メチルアミンの調製
|
EP2427192A1
(fr)
*
|
2009-05-07 |
2012-03-14 |
OSI Pharmaceuticals, LLC |
Utilisation d'osi-906 dans le traitement du carcinome adrénocortical
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
ES2731901T3
(es)
|
2009-07-06 |
2019-11-19 |
Boehringer Ingelheim Int |
Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
|
CA2766403A1
(fr)
|
2009-07-13 |
2011-01-20 |
Genentech, Inc. |
Procedes de diagnostic et compositions pour traitement d'un cancer
|
EP2459191A1
(fr)
|
2009-07-31 |
2012-06-06 |
OSI Pharmaceuticals, LLC |
Polythérapie par inhibiteur de mtor et inhibiteur de l angiogenèse
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
CA2772194A1
(fr)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Derives de benzimidazole
|
MX2012002862A
(es)
|
2009-09-11 |
2012-08-15 |
Genentech Inc |
Metodo para identificar un paciente con una mayor probabilidad de responder a un agente anticancerigeno.
|
CA2772670A1
(fr)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methodes et compositions utilisees a des fins de diagnostic chez les patients atteints du cancer
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
CN102639505A
(zh)
|
2009-10-02 |
2012-08-15 |
阿斯利康(瑞典)有限公司 |
用作嗜中性白细胞弹性蛋白酶抑制剂的吡啶-2-酮化合物
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(fr)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Dérivés d'amine cyclique ayant une activité agoniste de récepteur adrénergique bêta-2 et antagoniste de récepteur muscarinique
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
ES2522827T3
(es)
|
2009-10-30 |
2014-11-18 |
Domain Therapeutics |
Nuevos derivados de oximas y su uso como moduladores alostéricos de los receptores del glutamato metabotrópico
|
AR079050A1
(es)
|
2009-11-18 |
2011-12-21 |
Astrazeneca Ab |
Compuestos benzoimidazolicos y sus usos
|
MX359551B
(es)
|
2009-11-24 |
2018-10-02 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
JP2013512859A
(ja)
|
2009-12-03 |
2013-04-18 |
大日本住友製薬株式会社 |
トール様受容体(tlr)を介して作用するイミダゾキノリン
|
AU2010333338A1
(en)
|
2009-12-14 |
2012-08-02 |
Merck Patent Gmbh |
Sphingosine kinase inhibitors
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
WO2011073521A1
(fr)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations
|
AU2010341229A1
(en)
|
2009-12-17 |
2012-08-02 |
Merck Patent Gmbh |
Sphingosine kinase inhibitors
|
CN102203112B
(zh)
|
2010-01-15 |
2014-05-07 |
苏州润新生物科技有限公司 |
某些化合物、组合物及方法
|
AU2011208530A1
(en)
|
2010-01-19 |
2012-08-09 |
Astrazeneca Ab |
Pyrazine derivatives
|
WO2011095807A1
(fr)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinaisons d'inhibiteurs de mek et de hh
|
CN105001334A
(zh)
|
2010-02-10 |
2015-10-28 |
伊缪诺金公司 |
Cd20抗体及其用途
|
PT2534153T
(pt)
|
2010-02-12 |
2016-12-27 |
Pfizer |
Sais e polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona
|
AU2011223643A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109584A2
(fr)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
|
WO2011114148A1
(fr)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
Dérivés de 4h-[1,2,4]triazolo[5,1-b]pyrimidin-7-one à titre d'antagonistes des récepteurs ccr2b
|
WO2011153224A2
(fr)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Procédés diagnostiques et compositions de traitement du cancer
|
WO2011154677A1
(fr)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Composés n-[1-cyano-2-(phényl)éthyl] 1-aminocycloalk-1-ylcarboxamide substitués - 760
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
CN104689314B
(zh)
|
2010-06-16 |
2018-02-02 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
AU2011281702A1
(en)
|
2010-07-19 |
2013-01-31 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
MX2013000667A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
|
US20130177500A1
(en)
|
2010-07-23 |
2013-07-11 |
Trustee Of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
TW201219383A
(en)
|
2010-08-02 |
2012-05-16 |
Astrazeneca Ab |
Chemical compounds
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
WO2012042421A1
(fr)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Procédé de traitement de la croissance cellulaire anormale
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
EP2630134B9
(fr)
|
2010-10-20 |
2018-04-18 |
Pfizer Inc |
Dérivés de 2-pyridine comme modulateurs du récepteur smoothened
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
WO2012067269A1
(fr)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Composés aminoalcoxyphényle et leur utilisation dans le traitement de maladies
|
WO2012066335A1
(fr)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Composés phénol en tant qu'agonistes du récepteur 7 de type toll
|
WO2012066336A1
(fr)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Composés de benzylamine à titre d'agonistes du récepteur toll-like 7
|
EP2640716A1
(fr)
|
2010-11-19 |
2013-09-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Composés d'amides cycliques et leur utilisation dans le traitement de la maladie
|
ES2575688T3
(es)
|
2010-12-16 |
2016-06-30 |
Sumitomo Dainippon Pharma Co., Ltd. |
Derivado de imidazo[4,5-c]quinolin-1-ilo útil en terapia
|
DK2651943T3
(en)
|
2010-12-17 |
2017-06-06 |
Sumitomo Dainippon Pharma Co Ltd |
purine derivatives
|
CA2822515C
(fr)
|
2010-12-20 |
2023-04-25 |
Medimmune Limited |
Anticorps anti-il-18 et leurs applications
|
EP2670763B1
(fr)
|
2011-02-02 |
2018-08-01 |
Suzhou Neupharma Co., Ltd |
Certaines entités chimiques, compositions et procédés
|
KR20140010067A
(ko)
|
2011-02-15 |
2014-01-23 |
이뮤노젠 아이엔씨 |
컨쥬게이트의 제조방법
|
US9174946B2
(en)
|
2011-02-17 |
2015-11-03 |
Cancer Therapeutics Crc Pty Ltd |
Selective FAK inhibitors
|
CA2827171C
(fr)
|
2011-02-17 |
2019-04-09 |
Cancer Therapeutics Crc Pty Limited |
Inhibiteurs de fak
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
WO2012142164A1
(fr)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Anticorps monoclonaux humains qui se lient aux facteurs de croissance insulinomimétique (igf) de type i et ii
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
ES2724801T3
(es)
|
2011-04-19 |
2019-09-16 |
Pfizer |
Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
|
WO2012149014A1
(fr)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
|
WO2012175991A1
(fr)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Composés pentacycliques fusionnés anti-prolifératifs
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
CA2841859C
(fr)
|
2011-07-12 |
2021-03-09 |
Astrazeneca Ab |
N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio) pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide utilise en tant que modulateur du recepteur de chimiokine
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
CN105348266B
(zh)
|
2011-07-27 |
2018-04-10 |
阿斯利康(瑞典)有限公司 |
取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
AU2012300317B2
(en)
|
2011-08-26 |
2016-12-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2013033250A1
(fr)
|
2011-09-01 |
2013-03-07 |
Xiangping Qian |
Entités chimiques particulières, compositions et méthodes
|
CN104080455B
(zh)
|
2011-09-14 |
2018-07-31 |
润新生物公司 |
某些化学实体、组合物及方法
|
EP2757885B1
(fr)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Entités chimiques, compositions, et procédés spécifiques
|
EA201490673A1
(ru)
|
2011-09-22 |
2014-06-30 |
Пфайзер Инк. |
Производные пирролопиримидина и пурина
|
EP2760458B1
(fr)
|
2011-09-29 |
2017-06-14 |
The University of Liverpool |
Prévention et/ou traitement du cancer et/ou d'une métastase cancéreuse
|
WO2013049701A1
(fr)
|
2011-09-30 |
2013-04-04 |
Neupharma, Inc. |
Certaines entités chimiques, compositions et procédés
|
EP3275902A1
(fr)
|
2011-10-04 |
2018-01-31 |
IGEM Therapeutics Limited |
Anticorps ige anti-hmw-maa
|
US20140286959A1
(en)
|
2011-11-08 |
2014-09-25 |
Pfizer Inc. |
Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
WO2013112950A2
(fr)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Entités chimiques particulières, compositions et procédés
|
CA2862694C
(fr)
|
2012-01-28 |
2020-07-28 |
Merck Patent Gmbh |
Derives de triazolo[4,5-d]pyrimidine
|
SI2812323T1
(sl)
|
2012-02-09 |
2016-08-31 |
Merck Patent Gmbh |
Tetrahidro-kinazolinonski derivati kot zaviralci tank in parp
|
BR112014017762A8
(pt)
|
2012-02-09 |
2017-07-11 |
Merck Patent Gmbh |
Derivados de furo[3,2-b]- e tieno[3,2-b]piridina como inibidores de tbk1 e ikk, seus usos, processo para a preparação dos mesmos e medicamentos que os compreendem
|
CN104114558B
(zh)
|
2012-02-21 |
2016-10-26 |
默克专利股份公司 |
呋喃并吡啶衍生物
|
WO2013124026A1
(fr)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
2-amino-[1,2,4]triazolo[1,5-a]pyrazines substituées en 8ème position en tant qu'inhibiteurs de la tyrosine kinase syk et en tant qu'inhibiteurs de la sérine kinase gcn2
|
JP6059260B2
(ja)
|
2012-02-21 |
2017-01-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
環状ジアミノピリジン誘導体
|
CN104159901B
(zh)
|
2012-03-07 |
2016-10-26 |
默克专利股份公司 |
三唑并吡嗪衍生物
|
DK2831077T3
(en)
|
2012-03-28 |
2016-08-15 |
Merck Patent Gmbh |
BICYCLIC PYRAZINO DERIVATIVES
|
WO2013144532A1
(fr)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
Dérivés de pyrimidine 3-cyano-5-arylamino -7-cycloalkylaminopyrrolo [1, 5-a] et leurs utilisations comme agents antitumoraux
|
BR112014024903A2
(pt)
|
2012-04-05 |
2017-07-11 |
Hoffmann La Roche |
anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
|
WO2013152252A1
(fr)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Polythérapie antinéoplasique
|
EP2852285B1
(fr)
|
2012-04-29 |
2018-08-08 |
Neupharma, Inc. |
Dérivés bufadiènolides substitués en position 3 par un groupement amine hétérocyclique pour le traitement de cancer
|
JP6097820B2
(ja)
|
2012-05-04 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
ピロロトリアジノン誘導体
|
EP2859017B1
(fr)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
ES2611788T3
(es)
|
2012-06-26 |
2017-05-10 |
Sutro Biopharma, Inc. |
Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
|
WO2014015934A1
(fr)
|
2012-07-24 |
2014-01-30 |
Merck Patent Gmbh |
Dérivés d'hydroxystatine pour le traitement de l'arthrose
|
US9725462B2
(en)
|
2012-08-07 |
2017-08-08 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
JP6247294B2
(ja)
|
2012-08-08 |
2017-12-13 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
(アザ−)イソキノリノン誘導体
|
WO2014026243A1
(fr)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Inhibiteurs de vegfr3
|
EP2887965A1
(fr)
|
2012-08-22 |
2015-07-01 |
ImmunoGen, Inc. |
Dérivés de benzodiazépine cytotoxique
|
SI2890402T1
(sl)
|
2012-08-31 |
2019-07-31 |
Sutro Biopharma, Inc. |
Modificirane aminokisline vsebujoče acido skupino
|
WO2014041349A1
(fr)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Pyrimidines ou pyridazines tétrahydropyran-4-yléthylamino- ou tétrahydropyranyl-4-éthyloxy utiles comme inhibiteurs de l'isoprényl-cystéine-carboxy-méthyl-transférase
|
CN104812389B
(zh)
|
2012-09-24 |
2020-07-17 |
润新生物公司 |
某些化学实体、组合物及方法
|
KR102200628B1
(ko)
|
2012-09-26 |
2021-01-08 |
메르크 파텐트 게엠베하 |
Parp 억제제로서의 퀴나졸리논 유도체
|
EP2911692B1
(fr)
|
2012-10-26 |
2019-08-21 |
The University of Queensland |
Utilisation d'inhibiteurs de l'endocytose et d'anticorps pour une thérapie anticancéreuse
|
ES2674928T3
(es)
|
2012-11-05 |
2018-07-05 |
Gmdx Co Pty Ltd |
Métodos para determinar la causa de la mutagénesis somática
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
EP2920146B1
(fr)
|
2012-11-16 |
2016-09-28 |
Merck Patent GmbH |
Carboxamides de 3-aminocyclopentanes
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
ES2674087T3
(es)
|
2013-01-31 |
2018-06-27 |
Neomed Institute |
Compuestos de imidazopiridina y usos de los mismos
|
CN105189469B
(zh)
|
2013-02-25 |
2018-09-25 |
默克专利股份公司 |
2-氨基-3,4-二氢喹唑啉衍生物及其作为组织蛋白酶d抑制剂的用途
|
WO2014134486A2
(fr)
|
2013-02-28 |
2014-09-04 |
Immunogen, Inc. |
Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
|
EP2961434A2
(fr)
|
2013-02-28 |
2016-01-06 |
ImmunoGen, Inc. |
Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
|
CN105026397B
(zh)
|
2013-03-05 |
2017-06-30 |
默克专利股份公司 |
作为抗癌剂的9‑(芳基或杂芳基)‑2‑(吡唑基、吡咯烷基或环戊基)氨基嘌呤衍生物
|
PL2970205T3
(pl)
|
2013-03-14 |
2019-10-31 |
Tolero Pharmaceuticals Inc |
Inhibitory jak2 i alk2 oraz sposoby ich zastosowania
|
CN113398147A
(zh)
|
2013-03-15 |
2021-09-17 |
纽罗森特里亚股份有限公司 |
用于癌症的镁组合物及其用途
|
WO2014161570A1
(fr)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Anticorps dirigés contre l'il17 humaine et ses utilisations
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
WO2014194030A2
(fr)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
|
WO2014195507A1
(fr)
|
2013-06-07 |
2014-12-11 |
Universite Catholique De Louvain |
Dérivés de coumarine 3-carboxy substitués présentant une utilité potentielle dans le traitement des maladies cancéreuses
|
CA2916533C
(fr)
|
2013-06-25 |
2022-12-20 |
University Of Canberra |
Procedes et compositions de modulation des cellules souches cancereuses
|
EP3019522B1
(fr)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
|
HUE043465T2
(hu)
|
2013-08-23 |
2019-08-28 |
Neupharma Inc |
Kémiai anyagok, készítmények és módszerek
|
AU2014324092B2
(en)
|
2013-09-18 |
2020-02-06 |
Epiaxis Therapeutics Pty Ltd |
Stem cell modulation II
|
WO2015048852A1
(fr)
|
2013-10-01 |
2015-04-09 |
The University Of Queensland |
Trousses et procédés de diagnostic, dépistage, traitement et surveillance d'une maladie
|
WO2015051302A1
(fr)
|
2013-10-04 |
2015-04-09 |
Aptose Biosciences Inc. |
Compositions et procédés de traitement de cancers
|
WO2015054658A1
(fr)
|
2013-10-11 |
2015-04-16 |
Sutro Biopharma, Inc. |
Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
GB201321146D0
(en)
*
|
2013-11-29 |
2014-01-15 |
Cancer Rec Tech Ltd |
Quinazoline compounds
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
CN104829542B
(zh)
*
|
2014-02-10 |
2018-02-02 |
中国科学院上海药物研究所 |
苯胺嘧啶类化合物、其制备方法和医药用途
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
US10501805B2
(en)
|
2014-04-04 |
2019-12-10 |
Crown Bioscience, Inc. (Taicang) |
Methods for determining responsiveness to MEK/ERK inhibitors
|
WO2015155624A1
(fr)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dérivés de dihydropyrrolopyrimidine
|
BR112016024513A2
(pt)
|
2014-04-30 |
2017-08-15 |
Pfizer |
derivados de di-heterociclo ligados à cicloalquila
|
WO2016001789A1
(fr)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Epha4に対するヒトモノクローナル抗体及びそれらの使用
|
CN105330653A
(zh)
|
2014-08-11 |
2016-02-17 |
石药集团中奇制药技术(石家庄)有限公司 |
喹唑啉衍生物
|
CA2958704A1
(fr)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions pour moduler les cellules souches cancereuses et leurs utilisations
|
AU2015349613B2
(en)
|
2014-11-17 |
2022-01-13 |
The Council Of The Queensland Institute Of Medical Research |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
AU2016220219B2
(en)
|
2015-02-17 |
2020-05-14 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
RU2717829C2
(ru)
|
2015-04-20 |
2020-03-26 |
Толеро Фармасьютикалз, Инк. |
Прогнозирование ответа на альвоцидиб с помощью анализа профиля митохондрий
|
WO2016178876A2
(fr)
|
2015-05-01 |
2016-11-10 |
Cocrystal Pharma, Inc. |
Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
|
WO2016187316A1
(fr)
|
2015-05-18 |
2016-11-24 |
Tolero Pharmaceuticals, Inc. |
Promédicaments de l'alvocidib à biodisponibilité augmentée
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
WO2017009751A1
(fr)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Dérivés de pyrimidine
|
US10568887B2
(en)
|
2015-08-03 |
2020-02-25 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
AU2016302384B2
(en)
|
2015-08-04 |
2020-07-16 |
Aucentra Therapeutics Pty Ltd |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
CN108603231B
(zh)
|
2015-08-26 |
2023-06-30 |
Gmdx私人有限公司 |
检测癌症复发的方法
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
GB201519568D0
(en)
|
2015-11-05 |
2015-12-23 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
SG11201804360XA
(en)
|
2015-12-03 |
2018-06-28 |
Agios Pharmaceuticals Inc |
Mat2a inhibitors for treating mtap null cancer
|
CN117683769A
(zh)
|
2015-12-23 |
2024-03-12 |
瑞普鲁卡私人有限公司 |
核酸寡聚体及其用途
|
CN109069664B
(zh)
|
2016-01-27 |
2022-05-13 |
苏特罗生物制药公司 |
抗cd74抗体偶联物,包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
|
EP3411061A4
(fr)
|
2016-02-01 |
2019-07-10 |
University of Canberra |
Composés protéiques et leurs utilisations
|
GB201604182D0
(en)
|
2016-03-11 |
2016-04-27 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
WO2017162605A1
(fr)
|
2016-03-21 |
2017-09-28 |
Astrazeneca Ab |
Composés cinnolin-4-amine et leur utilisation pour traiter le cancer
|
MX2018012255A
(es)
|
2016-04-07 |
2019-02-07 |
Astrazeneca Ab |
Oxido de n, n-dimetil-3-[[5-(3-metil-2-oxo-1-tetrahidropiran-4-il- imidazo[4,5-c]quinolin-8-il)-2-piridil]oxi]propan-1-amina como modulador de cinasa atm (ataxia telangiectasia mutada) para el tratamiento del cancer.
|
RS63609B1
(sr)
|
2016-04-15 |
2022-10-31 |
Cancer Research Tech Ltd |
Heterociklična jedinjenja kao inhibitori ret kinaze
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
GB201608227D0
(en)
|
2016-05-11 |
2016-06-22 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
HUE059242T2
(hu)
|
2016-07-29 |
2022-11-28 |
Rapt Therapeutics Inc |
Azetidin-származékok mint kemokin receptor modulátorok és felhasználásuk
|
EP3497087B1
(fr)
|
2016-08-15 |
2021-11-10 |
Neupharma, Inc. |
Dérivés de pyrrolo[1,2-c]pyrimidine, imidazol[1,5-c]pyrimidine, quinazoline, purine et imidazo[1,5-a][1,3,5]triazine en tant qu'inhibiteurs de la tyrosine kinase pour le traitement du cancer
|
WO2018045379A1
(fr)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition et méthodes de traitement des déreglements des lymphocytes b
|
US10919896B2
(en)
|
2016-09-22 |
2021-02-16 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
EP3548478B1
(fr)
|
2016-12-05 |
2021-11-17 |
Apros Therapeutics, Inc. |
Composés de parimidines avec les groupes acidiques.
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
JP6619519B2
(ja)
|
2016-12-19 |
2019-12-11 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
プロファイリングペプチドおよび感受性プロファイリングのための方法
|
AU2017384388B2
(en)
|
2016-12-20 |
2020-09-17 |
Astrazeneca Ab |
Amino-triazolopyridine compounds and their use in treating cancer
|
CN110418789B
(zh)
|
2017-02-01 |
2022-03-25 |
常州千红生化制药股份有限公司 |
作为治疗剂的N-环烷基/杂环烷基-4-(咪唑并[1,2-a]吡啶)嘧啶-2-胺的衍生物
|
US10703723B2
(en)
|
2017-03-09 |
2020-07-07 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
JOP20190209A1
(ar)
|
2017-03-16 |
2019-09-12 |
Astrazeneca Ab |
مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
WO2018215798A1
(fr)
|
2017-05-26 |
2018-11-29 |
Cancer Research Technology Limited |
Inhibiteurs de bcl6 dérivés de 2-quinolone
|
EP4374858A3
(fr)
|
2017-05-26 |
2024-08-21 |
Cancer Research Technology Limited |
Dérivés de la benzimidazolone en tant qu'inhibiteurs du récepteur bcl6
|
WO2018220101A1
(fr)
|
2017-05-31 |
2018-12-06 |
Truly Translational Sweden Ab |
Composition pharmaceutique comprenant une association de méthotrexate et de novobiocine, et utilisation de ladite composition en thérapie
|
WO2019006157A1
(fr)
*
|
2017-06-28 |
2019-01-03 |
Vanderbilt University |
Composés de quinoléines pyridine utilisés en tant que potentialisateurs allostériques de mglur4, compositions, et méthodes de traitement de dysfonctionnements neurologiques
|
EP3648797A1
(fr)
|
2017-07-05 |
2020-05-13 |
EPOS-Iasis Research and Development, Ltd |
Conjugués multifonctionnels
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
KR20200035439A
(ko)
|
2017-08-01 |
2020-04-03 |
메르크 파텐트 게엠베하 |
아데노신 수용체 길항제로서의 티아졸로피리딘 유도체
|
US11447505B1
(en)
|
2017-08-18 |
2022-09-20 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
US11453647B2
(en)
|
2017-08-21 |
2022-09-27 |
Merck Patent Gmbh |
Benzimidazole derivatives as adenosine receptor antagonists
|
AU2018320672B2
(en)
|
2017-08-21 |
2023-09-07 |
Merck Patent Gmbh |
Quinoxaline derivatives as adenosine receptor antagonists
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
US10596270B2
(en)
|
2017-09-18 |
2020-03-24 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
|
WO2019057757A1
(fr)
|
2017-09-20 |
2019-03-28 |
Astrazeneca Ab |
Composés 1,3-dihydroimidazo[4,5-c]cinnolin-2-one et leur utilisation dans le traitement du cancer
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
CA3081750A1
(fr)
|
2017-11-06 |
2019-05-09 |
Rapt Therapeutics, Inc. |
Agents anticancereux
|
EP3489222A1
(fr)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sels de sulfasalazine, procédés de production et utilisations
|
EP3488868B1
(fr)
|
2017-11-23 |
2023-09-13 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Composition pharmaceutique pour administration orale contenant de la sulfasalazine et/ou un sel organique de sulfasalazine, procédé de production et utilisation
|
WO2019136514A1
(fr)
|
2018-01-15 |
2019-07-18 |
University Of South Australia |
Dérivés de 5-(pyrimidin-4-yl)thiazol-2-yl urée en tant qu'agents thérapeutiques
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
JP7355758B2
(ja)
|
2018-01-26 |
2023-10-03 |
ラプト・セラピューティクス・インコーポレイテッド |
ケモカイン受容体調節剤及びその使用
|
AU2019218893A1
(en)
|
2018-02-08 |
2020-09-03 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(fr)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Procédé de traitement du cancer du poumon
|
AU2019253510B2
(en)
|
2018-04-13 |
2023-08-10 |
Cancer Research Technology Limited |
BCL6 inhibitors
|
JP7427655B2
(ja)
|
2018-04-27 |
2024-02-05 |
スプルース バイオサイエンシーズ,インク. |
精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
AR114910A1
(es)
|
2018-06-04 |
2020-10-28 |
Apros Therapeutics Inc |
Compuestos de pirimidina que contienen grupos ácidos
|
US11046699B2
(en)
|
2018-06-05 |
2021-06-29 |
Rapt Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
EP3826684A4
(fr)
|
2018-07-26 |
2022-04-06 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Procédés de traitement de maladies associées à l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destinés à être utilisés dans ceux-ci
|
EP3852811A1
(fr)
|
2018-09-17 |
2021-07-28 |
Sutro Biopharma, Inc. |
Polythérapies avec des conjugués d'anticorps anti-récepteur du folate
|
WO2020057511A1
(fr)
|
2018-09-18 |
2020-03-26 |
Suzhou Zanrong Pharma Limited |
Dérivés de quinazoline en tant qu'agents antitumoraux
|
US11084829B2
(en)
|
2018-09-24 |
2021-08-10 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
|
CN112867715B
(zh)
|
2018-10-25 |
2024-03-05 |
默克专利股份公司 |
作为腺苷受体拮抗剂的5-氮杂吲唑衍生物
|
JP7551607B2
(ja)
|
2018-10-25 |
2024-09-17 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
KR20210099066A
(ko)
|
2018-12-04 |
2021-08-11 |
스미토모 다이니폰 파마 온콜로지, 인크. |
암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
|
US20230272402A1
(en)
|
2018-12-25 |
2023-08-31 |
Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences |
Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
CN113412262A
(zh)
|
2019-02-12 |
2021-09-17 |
大日本住友制药肿瘤公司 |
包含杂环蛋白激酶抑制剂的制剂
|
CN113795483A
(zh)
|
2019-03-07 |
2021-12-14 |
默克专利有限公司 |
作为shp2拮抗剂的甲酰胺-嘧啶衍生物
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
WO2020198077A1
(fr)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
JP2022528562A
(ja)
|
2019-04-05 |
2022-06-14 |
ストーム・セラピューティクス・リミテッド |
Mettl3阻害化合物
|
CN113646049B
(zh)
|
2019-04-08 |
2024-08-13 |
默克专利有限公司 |
作为shp2拮抗剂的嘧啶酮衍生物
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
EP3962951A1
(fr)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Conjugués d'anticorps anti-bcma
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
CA3152674A1
(fr)
|
2019-08-31 |
2021-03-04 |
Etern Biopharma (Shanghai) Co., Ltd. |
Derives de pyrazole pour l'inhibiteur des fgfr et methode de preparation connexe
|
TW202120501A
(zh)
|
2019-09-20 |
2021-06-01 |
美商愛德亞生物科學公司 |
作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
EP4069694A1
(fr)
|
2019-12-02 |
2022-10-12 |
Storm Therapeutics Ltd |
Composés polyhétérocycliques en tant qu'inhibiteurs de mettl3
|
WO2021155006A1
(fr)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
|
WO2021178597A1
(fr)
|
2020-03-03 |
2021-09-10 |
Sutro Biopharma, Inc. |
Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
US20230391770A1
(en)
|
2020-10-06 |
2023-12-07 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
WO2022074391A1
(fr)
|
2020-10-08 |
2022-04-14 |
Storm Therapeutics Limited |
Composés inhibiteurs de mettl3
|
EP3992191A1
(fr)
|
2020-11-03 |
2022-05-04 |
Deutsches Krebsforschungszentrum |
Dérivés d'imidazo[4,5-c]quinoline et leur utilisation en tant qu'inhibiteurs de kinase atm
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2022197641A1
(fr)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
Dérivés de 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine servant de modulateurs et/ou d'inhibiteurs de kinase progénitrice hématopoïétique 1 (hpk1) pour traiter le cancer et d'autres maladies
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
WO2022233718A2
(fr)
|
2021-05-03 |
2022-11-10 |
Merck Patent Gmbh |
Conjugués fragment-médicament de liaison à l'antigène fc ciblant her2
|
CA3220146A1
(fr)
|
2021-05-17 |
2022-11-24 |
Hk Inno.N Corporation |
Derive de benzamide, procede de preparation associe et composition pharmaceutique pour la prevention ou le traitement du cancer le contenant en tant que principe actif
|
WO2022248380A1
(fr)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Conjugués fragment de liaison à l'antigène fc-médicament ciblant l'egfr
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
CA3225500A1
(fr)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Composes inhibiteurs de parg
|
EP4413000A1
(fr)
|
2021-10-04 |
2024-08-14 |
FoRx Therapeutics AG |
Dérivés de n,n-diméthyl-4-(7-(n-(1-méthylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)pipérazine-1-carboxamide et dérivés correspondants de pyrazolo[1,5-a]pyridine utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer
|
AU2023205435A1
(en)
|
2022-01-10 |
2024-08-22 |
Cancer Research Horizons |
Substituted heterocycles as hset inhibitors
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175185A1
(fr)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer
|
WO2023175184A1
(fr)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer
|
WO2023186881A1
(fr)
|
2022-03-29 |
2023-10-05 |
Baden-Württemberg Stiftung Ggmbh |
Inhibiteurs de la map kinase p38 à utiliser dans le traitement du cancer colorectal
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
US20230322741A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024030825A1
(fr)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Sels cristallins de sels cristallins de (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-diméthyl-17-(2-oxo-2h-pyran-5-yl)hexadécahydro-1h-cyclopenta[a]phénanthren-3-yl pipérazine-1-carboxylate
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(fr)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Composé inhibiteur de parg
|
WO2024094962A1
(fr)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Dérivés de pyrido[2,3-d]pyrimidin-2-amine utilisés en tant qu'inhibiteurs d'egfr pour traiter le cancer
|
WO2024094963A1
(fr)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Dérivés de 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one et de 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1h)-one utilisés en tant qu'inhibiteurs d'egfr pour traiter le cancer
|
WO2024099898A1
(fr)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Inhibiteurs de hset bi-et tricycliques substitués
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
WO2024153128A1
(fr)
|
2023-01-18 |
2024-07-25 |
Shanghai Antengene Corporation Limited |
Composés inhibiteurs de prmt5 et leurs utilisations
|
WO2024173453A1
(fr)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Composés d'imidazopyridine à substitution hétéroaryle
|
WO2024173530A1
(fr)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Composés pyrazolo/imidazo pyridine à substitution hétéroaryle
|
WO2024173524A1
(fr)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Composés benzimidazoles à substitution hétéroaryle
|
WO2024173514A1
(fr)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Composés d'imidazopyridine à substitution amide et ester
|